Luminex Corporation Submits VERIGENE(R) II Respiratory Flex Assay for FDA Clearance
AUSTIN, Texas, March 2, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that the company has submitted an application to the U.S. Food and Drug Administration (FDA) for 510(k) clearance of the VERIGENE® II RespiratoryFlex Assay, the second VERIGENE II assay to be submitted...
Luminex Corporation to Acquire MilliporeSigma's Flow Cytometry Portfolio
- Strategic Deal Extends and Diversifies Company's Footprint in Life Science Research - Expands Luminex's Flow-based Instrument Offering Into Cellular Analysis with Acquisition of Amnis and Guava Branded Instruments - Transaction Expected to Close by End of 2018 AUSTIN, Texas, Oct. 22, 2018...
Luminex Corporation's VERIGENE Gram-Positive and Gram-Negative Blood Culture Panels Receive Reimbursement Approval in Japan
AUSTIN, Texas, June 12, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) recently announced that Japan's Central Social Insurance Medical Council has approved the recommendation by the Japanese Ministry of Health, Labor and Welfare (MHLW) to provide reimbursement for two VERIGENE® assays:...
Luminex Corporation Completes Acquisition of Nanosphere, Inc.
AUSTIN, Texas, July 5, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that Luminex has completed its previously announced acquisition of Nanosphere, Inc. (NASDAQ: NSPH) "We are pleased to announce the completion of this transaction and welcome the Nanosphere team to the ...
Luminex Corporation to Showcase CE-IVD Marked ARIES System, Revolutionary Software, and Assays at ECCMID Annual Meeting
AUSTIN, Texas, April 7, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it will showcase its recently CE-IVD marked, sample to answer ARIES® molecular diagnostic system and related assays at the annual meeting of the European Society of Clinical Microbiology and Infec...
